Drug Trial Radar · NCT01617772
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis
Last checked: Nov 19, 2026Latest source record: May 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
440
Planned (sponsor's estimate)
Start
Jan 1, 2016
Primary completion
Oct 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Tehran University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin, L-Carnitine monotherapy on liver transaminases and liver elasticity in NASH patients.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
AtorvastatinDrug
Atorvastatin 20 mg
L-CarnitineDrug
1000mg L-carnitine
PlaceboDrug
Identically looking placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- improvement in liver stiffnessTime frame: 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Masoud Clinic
Tehran, Iran · Recruiting
Pars Cohort Center
Shiraz, Fars, Iran · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.